Extensive rhabdomyosarcomatous differentiation in recurrent low-grade urothelial carcinoma of the bladder after transurethral resection: a case report

Maiko Kamei¹, Tsutomu Shinohara²*, Kotaro Kasahara¹, Takahira Kuno¹, Keishi Naruse³ and Hironobu Watanabe¹

**Abstract**

**Introduction:** Sarcomatoid carcinoma of the urinary bladder is a rare bidirectional malignant neoplasm with epithelial and mesenchymal differentiation. The epithelial component is mainly high-grade urothelial carcinoma, and the mesenchymal component includes rhabdomyosarcoma. However, proper differential diagnosis of adult rhabdomyosarcomatous tumors of the bladder can be a challenge. Moreover, low-grade urothelial carcinoma as the epithelial component of sarcomatoid carcinoma has not been reported.

**Case presentation:** A 64-year-old Asian man with a history of transurethral resection of low-grade urothelial carcinoma of the bladder visited our department with complaints of frequent urination and macroscopic hematuria. Computed tomography and magnetic resonance imaging demonstrated a large mass located in the anterior wall of the bladder. Pathological diagnosis of transurethral biopsy was low-grade, non-invasive papillary urothelial carcinoma, and tumor tissue was removed by total cystectomy. Immunohistochemical studies and fluorescence in situ hybridization assay of the resected neoplastic tissue revealed extensive rhabdomyosarcomatous differentiation causing the formation of a large pedunculated polyp with a papillary appearance of recurrent low-grade urothelial carcinoma. No evidence of recurrence was detected during 2 years of follow-up without further treatment.

**Conclusions:** Urothelial carcinoma of the urinary bladder with extensive rhabdomyosarcomatous differentiation is rare, but it should be considered in the differential diagnosis even when urothelial carcinoma coexisting with a rhabdomyosarcomatous component is low-grade and non-invasive.

**Keywords:** Sarcomatoid carcinoma, Urothelial carcinoma, Rhabdomyosarcomatous differentiation, Transurethral resection, Anaplastic lymphoma kinase

**Introduction**

Sarcomatoid carcinoma (SC) is a rare bidirectional malignant neoplasm with epithelial and mesenchymal differentiation that accounts for less than 0.3% of all histological subtypes of primary urinary bladder tumors [1, 2]. The epithelial component is mainly high-grade urothelial carcinoma (UC), and the mesenchymal malignant component consists of osteosarcoma, chondrosarcoma, rhabdomyosarcoma (RMS), and so forth [1]. Inflammatory myofibroblastic tumor (IMT), also referred to as inflammatory pseudotumor, pseudosarcomatous fibromyxoid tumor, and post-operative spindle cell nodule, is an unusual, benign, myofibroblastic spindle cell lesion that can arise from various organs, including the urinary bladder. IMT of the bladder manifests prominent nucleoli, mitoses, chromosomal abnormalities, necrosis, and muscularis propria invasion, resembling malignant spindle cell tumors, including pure RMS, leiomyosarcoma, and SC [3, 4].

Clinically, proper differential diagnosis of adult rhabdomyosarcomatous tumors of the urinary bladder, including pure RMS, UC, and IMT, can be a challenge. In this report, we present a case of recurrent low-grade UC with extensive rhabdomyosarcomatous differentiation in an elderly man. The lesion presented as a large mass due to a rhabdomyosarcomatous component at the first medical examination. To the best of our knowledge,
this is the first reported case of low-grade UC as the epithelial component of SC.

Case presentation
A 52-year-old Asian man underwent transurethral resection (TUR) of stage I (T1N0M0) low-grade UC (transitional cell carcinoma [TCC]) in the anterior wall of the bladder at a nearby hospital. He was referred to our hospital 4 months after undergoing TUR. Cytoscopic examination performed at our division showed scar formation after TUR with negative biopsies, and he did not wish to undergo further treatment. Although we planned follow-up studies, he stopped visiting our hospital just after the cytoscopic examination. At the age of 64, 12 years after undergoing TUR, he visited our department with complaints of frequent urination and macroscopic hematuria without painful micturition. During his physical examination, a pelvic mass and superficial lymph nodes were not palpable, but computed tomography (CT) and magnetic resonance imaging (MRI) demonstrated a large mass (3.8cm×2.9cm) with infiltration into the muscle layer (T2b), which was located in the anterior wall of the urinary bladder. The mass intensity was the same as in the rest of the bladder wall on T1-weighted images (Fig. 1a, b). Urinary cytology was positive and suggestive of UC (TCC). Cytoscopic examination revealed a large pedunculated polyp with a surrounding papillary appearance. The patient subsequently underwent a transurethral biopsy of the tumor. The pathological diagnosis was low-grade, non-invasive papillary UC (Ta), and there was no evidence of metastasis on CT or MRI. Although muscularis propria invasion was not observed in the transurethral biopsy specimens, the patient was diagnosed with stage II (T2bN0M0) UC on the basis of MRI findings of tumor infiltration into the muscle layer. Therefore, tumor tissue was removed by total cystectomy (Fig. 1c), and bilateral pelvic lymph node dissection of external iliac and obturator regions with ileal conduit urinary diversion was performed. In total, eight lymph nodes were dissected. No post-operative complications were observed.

The final diagnosis of low-grade UC (TCC) with rhabdomyosarcomatous differentiation (INFa, pTa [epithelial component]/pT2b [mesenchymal component], LV10, RM0, u-r0, u-lt0, ur0, N0, M0) was established on the basis of immunohistochemical studies and fluorescence in situ hybridization (FISH) assay of the resected neoplastic tissue. The pedunculated polyp was made up mainly of a sarcomatous component with a spindle cell–like appearance, which was characterized by severe nuclear pleomorphism and mitotic activity (Fig. 2a), and scattered areas of necrosis. Some strap- and racket-shaped cells with eosinophilic elongated cytoplasm were present in a dispersed manner (Fig. 2a). Spindle-like cells were positive for vimentin (Fig. 2b), myogenin, and desmin, suggesting rhabdomyosarcomatous differentiation. In contrast, these cells were negative for cytokeratins recognized by AE1/
AE3 (Fig. 2c), chromogranin, synaptophysin, α-smooth muscle actin, and anaplastic lymphoma kinase (ALK) (Fig. 2d). Rearrangements and copy number gain of the ALK gene were not detected by FISH (Fig. 2e). Muscularis propria invasion (T2b) was observed in the sarcomatous lesion without lymph node metastasis. The epithelial component of the tumor, which was consistent with a papillary lesion surrounding the pedunculated polyp, was low-grade, non-invasive UC (TCC) without necrosis (Fig. 2f). The rate of positivity of urinary cytology in patients with low-grade UC (TCC) is about 25% at our institute. The status of X chromosome inactivation and loss of heterozygosity (LOH) in both the carcinomatous and sarcomatous components was not analyzed. No evidence of recurrence was detected by whole-body CT during a 2-year follow-up period without further treatment.

Discussion
In our patient, transurethral biopsy revealed UC but not a sarcomatous component, owing to inadequate sampling. However, the reverse situation has been reported by others. Depending on the circumstances, a small focus of carcinomatous component may be detectable only by extensive, multiple sampling. Therefore, in the case of adult rhabdomyosarcomatous tumor, the diagnosis of pure RMS should be made very carefully [5].

The other difficulty is differentiating this case from IMT. Although both epithelial and myogenic markers can be expressed in IMT, a morphologically typical epithelial component is not interwoven with IMT [4, 6]. Moreover, recent studies have shown that the majority of IMT express ALK protein, and FISH analysis has identified ALK gene alterations within myofibroblastic spindle cells of IMT, suggesting an etiology of a low-grade mesenchymal neoplasm other than primary inflammatory reaction [3, 4, 6]. However, our patient’s tumor was a typical epithelial carcinoma, and ALK protein expression and ALK alterations of the rhabdomyosarcomatous component were both negative.

The accurate histogenesis of SC has not been clarified in detail. Although multiclonal theory and monoclonal theory have been discussed, molecular and genetic research using LOH, comparative genomic hybridization, and X chromosome inactivation analysis substantiate a common origin with divergent differentiation [7]. Previous studies have suggested that the epithelial component of SC of the bladder precedes the mesenchymal component [8]. The tumor in our patient may initially have exhibited...
Conclusions

UC of the urinary bladder with extensive rhabdomyosarcomatous differentiation is rare, but it should be considered in the differential diagnosis even when UC coexisting with a rhabdomyosarcomatous component is of low grade, especially in cases of a tumor that is unexpectedly large for low-grade UC. More molecular biological research is needed to obtain insight into the pathogenic factors involved in rhabdomyosarcomatous differentiation in UC to improve the management of this disease.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent form is available for review by the Editor-in-Chief of this journal.

Abbreviations

ALK: Anaplastic lymphoma kinase; CT: Computed tomography; FISH: Fluorescence in situ hybridization; IMT: Inflammatory myofibroblastic tumor; LOH: Loss of heterozygosity; MRI: Magnetic resonance imaging; RMS: Rhabdomyosarcoma; SC: Sarcomatoid carcinoma; TCC: Transitional cell carcinoma; TUR: Transurethral resection; UC: Urothelial carcinoma.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

MK drafted the initial manuscript. TS edited and submitted the manuscript for publication. KK and TK were involved in diagnosing and treating the patient. KN performed pathological studies. HW was the attending physician throughout the patient’s disease course. All authors read and approved the final manuscript.

Acknowledgments

We thank Yukihisa Komatsu (Division of Radiology, National Hospital Organization National Kochi Hospital, Kochi, Japan) for his contribution to this article.

Received: 26 February 2015 Accepted: 20 August 2015
Published online: 10 September 2015

References

1. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. World Health Organization classification of tumors: pathology and genetics of tumors of the urinary system and male genital organs. Lyon: IARC Press; 2004. p. 99–133.
2. Wang J, Wang FW, Lagrange CA, Hemstreet 3rd GP, Kessinger A. Clinical features of sarcomatoid carcinoma (carcinosarcoma) of the urinary bladder: analysis of 221 cases. Sarcoma. 2010;2010:454792. doi:10.1155/2010/454792.
3. Montgomery EA, Shuster DD, Burkart AL, Esteban JM, Srigiognoli A, Elwood L, et al. Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma. Am J Surg Pathol. 2006;30:1502–12.
4. Alderman M, Kunju LP. Inflammatory myofibroblastic tumor of the bladder. Arch Pathol Lab Med. 2014;138:1272–7.
5. Bing Z, Zhang PJ. Adult urinary bladder tumors with rhabdomyosarcomatous differentiation: clinical, pathological and immunohistochemical studies. Diagn Pathol. 2011;6:66.
6. Sukov WR, Cheville JC, Carlson AW, Shearer BM, Paistigonsky EJ, Grogg KL, et al. Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. Mod Pathol. 2007;20:592–603.
7. Sung MT, Wang M, MacLennan GT, Eble JN, Tan PH, Lopez-Beltran A, et al. Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: evidence for a common clonal origin with divergent differentiation. J Pathol. 2007;211:420–30.
8. Cheng L, Zhang S, Alexander R, MacLennan GT, Hodges KB, Harrison BT, et al. Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am J Surg Pathol. 2011;35:e34–46.
9. Isegami H, Iwasaki H, Ohjimi Y, Takeuchi T, Aiyoshi T, Kikkuchi M. Sarcomatoid carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 14 patients. Hum Pathol. 2000;31:332–40.
10. Stamatiou K, Galariotis N, Michailidis I, Petrikopoulou N, Moustou H, Zizi-Sermpetzoglou A. Sarcomatoid carcinoma of the urinary bladder: a clinicopathological study of 4 cases and a review of the literature. Korean J Urol. 2010;51:724-8.

11. Mitrakas LP, Zachos IV, Tzortzis VP, Gravas SA, Rouka EC, Dimitropoulos KI, et al. Previous bladder cancer history in patients with high-risk, non-muscle-invasive bladder cancer correlates with recurrence and progression: implications of natural history. Cancer Res Treat. 2015;47:495–500. doi:10.4143/crt.2014.050.

12. Michaud DS. Chronic inflammation and bladder cancer. Urol Oncol. 2007;25:260-8.

13. Wright JL, Black PC, Brown GA, Porter MP, Kamat AM, Dinney CP, et al. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol. 2007;178:2302-6.

14. Antonelli A, Simeone C, Ferrari V, Tardanico R, Cunico SC. Durable and complete remission of a metastatic bladder sarcomatoid carcinoma with chemotherapeutic and surgical treatments. Arch Ital Urol Androl. 2006;78:67-70.

15. Onal C, Pehliyan B, Bal N, Topkân E, Kilinc F, Topuk S. Sarcomatoid carcinoma of the urinary bladder treated with adjuvant radiotherapy: a case report. Clin Med Case Rep. 2009;2:39-42.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit